MTOR and neoplasm: Direct and indirect evidence of active mTORC1 signaling have been reported in several types of NH B-cell lymphomas and correlated with tumor cell proliferation and resistance to immuno-chemotherapy, thus providing a rationale for testing mTOR-targeted therapies in refractory/relapsed NH B-cell lymphomas.